10,475 Shares in Neurogene Inc. (NASDAQ:NGNE) Bought by Mariner LLC

Mariner LLC purchased a new stake in shares of Neurogene Inc. (NASDAQ:NGNE) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 10,475 shares of the company’s stock, valued at approximately $239,000. Mariner LLC owned approximately 0.07% of Neurogene as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in NGNE. Barclays PLC raised its holdings in shares of Neurogene by 18.0% during the 4th quarter. Barclays PLC now owns 17,533 shares of the company’s stock valued at $401,000 after buying an additional 2,674 shares in the last quarter. Wells Fargo & Company MN grew its position in Neurogene by 34.5% during the fourth quarter. Wells Fargo & Company MN now owns 5,444 shares of the company’s stock valued at $124,000 after acquiring an additional 1,397 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Neurogene by 6.4% during the fourth quarter. Geode Capital Management LLC now owns 234,625 shares of the company’s stock worth $5,365,000 after acquiring an additional 14,026 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Neurogene by 18.7% in the 4th quarter. Wellington Management Group LLP now owns 21,717 shares of the company’s stock worth $496,000 after acquiring an additional 3,427 shares during the last quarter. Finally, Blair William & Co. IL purchased a new stake in shares of Neurogene in the 4th quarter valued at $1,432,000. Institutional investors own 52.37% of the company’s stock.

Neurogene Price Performance

NASDAQ NGNE opened at $13.05 on Wednesday. Neurogene Inc. has a 1 year low of $6.88 and a 1 year high of $74.49. The stock has a market capitalization of $186.12 million, a PE ratio of -3.06 and a beta of 1.56. The business’s 50-day moving average is $13.62 and its 200 day moving average is $22.24.

Neurogene (NASDAQ:NGNE) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.99) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.05. The business had revenue of $0.93 million during the quarter. As a group, equities research analysts anticipate that Neurogene Inc. will post -4.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on NGNE. William Blair reiterated an “outperform” rating on shares of Neurogene in a research report on Tuesday, March 25th. BMO Capital Markets decreased their price objective on Neurogene from $45.00 to $16.00 and set an “outperform” rating on the stock in a report on Monday, April 14th. HC Wainwright dropped their target price on Neurogene from $55.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, March 25th. Finally, Robert W. Baird set a $38.00 price target on Neurogene in a research note on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Neurogene has a consensus rating of “Buy” and an average price target of $47.20.

Insider Buying and Selling at Neurogene

In other news, CFO Christine Mikail Cvijic sold 4,501 shares of Neurogene stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $16.94, for a total transaction of $76,246.94. Following the sale, the chief financial officer now owns 72,343 shares of the company’s stock, valued at approximately $1,225,490.42. The trade was a 5.86 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 9.92% of the company’s stock.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.